- Bond yields steady before payrolls after week of big price gains
- These analysts say the office and apartment building worries after NYCB are like Groundhog Day — but do concede one issue
- Car loaded with gas in Kenya explodes and sets off inferno that injures more than 270, kills at least 33
- Barron's Energy Stocks Have Struggled. Why They Shine as Dividend Payers.
- Barron's Philip Morris Stock Stands to Get a Boost From Earnings
- Barron's Brazil Is Having a Great Time. 5 Stocks to Play.
- Barron's Boeing’s Troubles Aren’t Going Away. How to Profit From Its Problems.
- Barron's The 6% Commission for Home Sales Is Under Attack. Inside the Fight to Keep It Alive.
- Prosecutors weigh perjury charge for ex-Trump CFO Allen Weisselberg over civil fraud trial testimony
- Shares of China’s Landsea Green rise on plan to buy Texas homebuilder for $185 million
to be replaced
Evotec SE ADR
$
7.55
Close | Chg | Chg % |
---|---|---|
$7.52 | -0.23 | -2.91% |
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
EVO Overview
Key Data
- Open $7.64
- Day Range 7.34 - 7.64
- 52 Week Range 7.34 - 13.49
- Market Cap $2.76B
- Shares Outstanding 355.08M
- Public Float 282.3M
- Beta 0.84
- Rev. per Employee $159.48K
- P/E Ratio N/A
- EPS -$0.38
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 2.49K 01/12/24
- % of Float Shorted 0.00%
- Average Volume 61.35K
Performance
5 Day |
|
1 Month |
|
3 Month |
|
YTD |
|
1 Year |
|
Analyst Ratings
Recent News
Eaton Vance Ohio Municipal Income Trust downgraded to hold from buy at Stifel Nicolaus
What's Going On With Life Science Company Evotec Stock Today?
Why Is Mobileye (MBLY) Stock Down 26% Today?
Can TikTok Save Peloton (PTON) Stock?
Why Is Evotec (EVO) Stock Down 12% Today?
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
A Preview Of Evotec's Earnings
Is Evolution a Prime Opportunity Following 3rd-Quarter Results?
Is Evolution a Prime Opportunity Following 3rd-Quarter Results?
What 4 Analyst Ratings Have To Say About Evotec
Evotec SE ADR
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Competitors
Name | Chg % | Market Cap |
---|---|---|
United States Steel Corp. | $10.52B | |
AstraZeneca PLC ADR | $207.28B | |
Johnson & Johnson | $382.52B | |
Novartis AG ADR | $215.54B |